Prevalence and severity of fatigue in psoriasis and psoriatic arthritis

Krajewska–Włodarczyk, Magdalena; Owczarczyk‐Saczonek, Agnieszka; Placek, Waldemar

doi:10.5114/ada.2019.83629

Cited by 6 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Well-known factors that can affect response to PsA treatment include female sex and pre-existing obesity. These observations may relate to females, who have longer PsA disease duration, higher BMI, higher disease severity scores and increased central sensitisation compared with males,32–34 reporting more severe fatigue and poorer physical function than males 32 35–37. Consistent with these predisposing factors, a numerically smaller proportion of females than males achieved an MDA response at weeks 24 and 52, though a similar trend in greater achievement of MDA response at weeks 24 and 52 with guselkumab versus placebo was seen for both the Q4W and Q8W guselkumab dosing regimens in both males and females.…”

Section: Discussionmentioning

confidence: 87%

Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies

et al. 2022

View full text Add to dashboard Cite

ObjectivesTo evaluate the efficacy through 52 weeks of guselkumab, an interleukin 23-p19 subunit inhibitor, in subgroups of pooled psoriatic arthritis (PsA) patients from the DISCOVER-1 and DISCOVER-2 trials defined by baseline patient characteristics.MethodsAdults with active PsA despite standard therapies were enrolled in DISCOVER-1 (≥3 swollen and ≥3 tender joints, C reactive protein (CRP) level ≥0.3 mg/dL) and DISCOVER-2 (≥5 swollen and ≥5 tender joints, CRP ≥0.6 mg/dL, biological-naïve). Randomised patients received 100 mg guselkumab at weeks 0, 4, and then every 4 or 8 weeks (Q4W/Q8W) or placebo. Guselkumab effects on joint (ACR20/50/70), skin (IGA 0/1, IGA 0), patient-reported outcome (Health Assessment Questionnaire Disability Index/Functional Assessment of Chronic Illness Therapy-Fatigue) and disease severity (minimal disease activity/PsA Disease Activity Score low disease activity) endpoints were evaluated by patient sex, body mass index, PsA duration, swollen/tender joint counts, CRP level, percent body surface area with psoriasis, Psoriasis Area and Severity Index score, and conventional synthetic disease-modifying antirheumatic drug use at baseline.ResultsBaseline patients characteristics in DISCOVER-1 (N=381) and DISCOVER-2 (N=739) were well balanced across randomised groups. At week 24, 62% (232/373) and 60% (225/375), respectively, of guselkumab Q4W-treated and Q8W-treated patients pooled across DISCOVER-1 and DISCOVER-2 achieved the primary endpoint of ACR20 response versus 29% (109/372) of placebo-treated patients. Guselkumab treatment effect at week 24 was observed across patient subgroups. Within each patient subgroup, response rates across all disease domains were sustained or increased at week 52 with both guselkumab regimens.ConclusionsGuselkumab Q4W and Q8W resulted in robust and sustained improvements in PsA signs and symptoms consistently in subgroups of patients defined by diverse baseline characteristics.Trial registration numbersNCT03162796, NCT03158285.

show abstract

Section: Discussionmentioning

confidence: 87%

Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In different studies, fatigue was more frequently reported among patients with PsA than patients with cutaneous psoriasis alone and, according to that, more than half of our sample suffered from moderate to severe fatigue (27,28). Depression is a recognized but understudied comorbidity in patients with PsA, and according to the PHQ-9 questionnaire, 40% of the subjects had moderate to very severe depression.…”

Section: Discussionmentioning

confidence: 51%

Section: Discussionmentioning

confidence: 54%

Critical importance of patient-reported outcomes for a comprehensive assessment of psoriatic arthritis patients

Lo Monaco,

Mallaci Bocchio,

Natoli

et al. 2024

Front. Med.

View full text Add to dashboard Cite

IntroductionPsoriatic arthritis (PsA) is a heterogeneous, chronic inflammatory disease that negatively impacts patients’ quality of life. Patient-reported outcome measures (PROMs) are used to capture patient perspectives in disease assessment, and physicians use the Disease Activity Index for Psoriatic Arthritis (DAPSA) to evaluate disease activity in PsA. The study aimed to assess the relationship between PROMs and the DAPSA score in consecutive outpatients affected by PsA.Materials and methodsA cross-sectional study was conducted from March 2018 to October 2020 at the PsA clinic of the ARNAS Civico in Palermo (Italy), enrolling outpatients with PsA. Patients were assessed for their disease activity according to the DAPSA score, and PROMs, such as PHQ-9, HAQ, FACIT-F, and PsAID, were evaluated. Linear regression analysis evaluated the relationship between the DAPSA Score and the included PROMs.Results158 PsA consecutive peripheral subset psoriatic arthritis outpatients were recruited. The median years of illness was 10.6 (9.3–11.9), and the median DAPSA score was 19.02 (9–33.1). The regression analysis highlighted a strong relationship between the DAPSA score and the PsAID (adjR2 26%, p < 0.0001), the FACIT-F (adjR2 25.4%, p < 0.0001), the HAQ (adjR2 23.7%, p < 0.0001), and PHQ-9 (adjR2 15%, p < 0.0001).ConclusionPROMs are strongly associated with the DAPSA score, but it allows in-depth evaluation of the impact of the disease on different domains of PsA patients’ life.

show abstract